Discovery of Adjuvants for mRNA Vaccines

NIH Pandemic-Era Grants

Pandemic Era Grants

2024

↗ Live URL (may be dead)

Document text

Principal Investigator: DENNIS  CARSON
Organization: UNIVERSITY OF CALIFORNIA, SAN DIEGO
Fiscal Year: 2024
Award: $2,601,750
Funding agency: National Institute of Allergy and Infectious Diseases

The offeror’s proposed work plan aims to identify, characterize and optimize non-toxic, low 
molecular weight agents as adjuvants that a) enhance protein antigen accumulation and release in non-immune and immune cells after 
intramuscular administration of mRNA vaccine and b) stimulate innate immune pathway-activation in antigen presenting cells.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV vaccine><Adjuvant><Antigen-Presenting Cells><Antigens><Assay><Bioassay><Biochemical><Biological Assay><COVID-19 vaccine><COVID-19 virus><COVID19 virus><Cell Body><Cell Survival><Cell Viability><Cells><CoV-2><CoV2><Dose><Formulation><Genetic><High Throughput Assay><Human><Immune><Immune Cell Activation><Immunes><Immunology procedure><Intramuscular><Lead><Lytotoxicity><Messenger RNA><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Molecular Weight><Murine><Mus><Pb element><Preparation><Protein Biosynthesis><Proteins><RNA vaccine><RNA-based vaccine><Ribosomal Peptide Biosynthesis><Ribosomal Protein Biosynthesis><Ribosomal Protein Synthesis><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 vaccine><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Safety><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Structure-Activity Relationship><Transfection><Work><Wuhan coronavirus><accessory cell><analog><chemical structure function><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease-19 vaccine><coronavirus disease-19 virus><cytotoxicity><design><designing><hCoV19><heavy metal Pb><heavy metal lead><high throughput screening><immune activation><immunogen><immunologic assay><immunologic assay/test><innate immune pathways><lipid based nanoparticle><lipid nanoparticle><mRNA><mRNA vaccine><mRNA-based vaccine><mouse model><murine model><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><novel><pre-clinical study><preclinical study><preparations><protective efficacy><protein synthesis><scaffold><scaffolding><scale up><structure function relationship><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine candidates against SARS-CoV-2><vaccine for novel coronavirus><vaccine formulation><vaccines preventing COVID><vaccines to prevent COVID>